Doomsday postponed? Preventing and reversing epidemics of drug-resistant tuberculosis (original) (raw)

• Raviglione, M. C. & Uplekar, M. W. WHO's new stop TB strategy. Lancet 367, 952–955 (2006).
  Article Google Scholar
• World Health Organization. Anti-tuberculosis drug resistance in the world: report no. 3 (WHO, Geneva, 2004).
• Singh, J. A., Upshur, R. & Padayatchi, N. XDR-TB in South Africa: no time for denial or complacency. PLoS Med. 4, e50 (2007).
  Article Google Scholar
• Koenig, R. Drug-resistant tuberculosis. In South Africa, XDR TB and HIV prove a deadly combination. Science 319, 894–897 (2008).
  Article Google Scholar
• Jones, K. D., Hesketh, T. & Yudkin, J. Extensively drug-resistant tuberculosis in sub-Saharan Africa: an emerging public-health concern. Trans. R. Soc. Trop. Med. Hyg. 102, 219–224 (2008).
  Article Google Scholar
• World Health Organization. Anti-tuberculosis drug resistance in the world: report no. 4 (WHO, Geneva, 2008).
• von Gottberg, A. et al. Emergence of levofloxacin-non-susceptible Streptococcus pneumoniae and treatment for multidrug-resistant tuberculosis in children in South Africa: a cohort observational surveillance study. Lancet 371, 1108–1113 (2008).
  Article Google Scholar
• Hancock, R. E. W. The end of an era? Nature Rev. Drug Discov. 6, 28 (2007).
  Article CAS Google Scholar
• Raviglione, M. XDR-TB: entering the post-antibiotic era? Int. J. Tuberc. Lung Dis. 10, 1185–1187 (2006).
  PubMed Google Scholar
• Norrby, S. R., Nord, C. E. & Finch, R. Lack of development of new antimicrobial drugs: a potential serious threat to public health. Lancet Infect. Dis. 5, 115–119 (2005).
  Article Google Scholar
• Levy, S. B. & Marshall, B. Antibacterial resistance worldwide: causes, challenges and responses. Nature Med. 10, S122–S129 (2004).
  Article CAS Google Scholar
• Spigelman, M. K. New tuberculosis therapeutics: a growing pipeline. J. Infect. Dis. 196 (Suppl. 1), 28–34 (2007).
  Article Google Scholar
• Glickman, S. W., Rasiel, E. B., Hamilton, C. D., Kubataev, A. & Schulman, K. A. A portfolio model of drug development for tuberculosis. Science 311, 1246–1247 (2006).
  Article CAS Google Scholar
• Dye, C. & Espinal, M. A. Will tuberculosis become resistant to all antibiotics? Proc. R. Soc. Lond. B 268, 45–52 (2001).
  Article CAS Google Scholar
• World Health Organization. The global MDR-TB and XDR-TB response plan 2007–2008 (WHO, Geneva, 2007).
• Dye, C., Espinal, M. A., Watt, C. J., Mbiaga, C. & Williams, B. G. Worldwide incidence of multidrug-resistant tuberculosis. J. Infect. Dis. 185, 1197–1202 (2002).
  Article Google Scholar
• Zignol, M. et al. Global incidence of multidrug-resistant tuberculosis. J. Infect. Dis. 194, 479–485 (2006).
  Article Google Scholar
• Cohen, T. et al. Challenges in estimating the total burden of drug-resistant tuberculosis. Am. J. Respir. Crit. Care Med. 177, 1302–1306 (2008).
  Article Google Scholar
• Ben Amor, Y., Nemser, B., Singh, A., Sankin, A. & Schluger, N. Underreported threat of multidrug-resistant tuberculosis in Africa. Emerg. Infect. Dis. 14, 1345–1352 (2008).
  Article Google Scholar
• Shah, N. S. et al. Worldwide emergence of extensively drug-resistant tuberculosis. Emerg. Infect. Dis. 13, 380–387 (2007).
  Article CAS Google Scholar
• Pillay, M. & Sturm, A. W. Evolution of the extensively drug-resistant F15/LAM4/KZN strain of Mycobacterium tuberculosis in KwaZulu-Natal, South Africa. Clin. Infect. Dis. 45, 1409–1414 (2007).
  Article CAS Google Scholar
• Gandhi, N. R. et al. Extensively drug-resistant tuberculosis as a cause of death in patients co-infected with tuberculosis and HIV in a rural area of South Africa. Lancet 368, 1575–1580 (2006).
  Article Google Scholar
• Dye, C. & Espinal, M. A. Will tuberculosis become resistant to all antibiotics? Proc. R. Soc. Lond. B 268, 45–52 (2001).
  Article CAS Google Scholar
• Dye, C. & Williams, B. G. Criteria for the control of drug-resistant tuberculosis. Proc. Natl Acad. Sci. USA 97, 8180–8185 (2000).
  Article CAS Google Scholar
• Dye, C., Williams, B. G., Espinal, M. A. & Raviglione, M. C. Erasing the world's slow stain: strategies to beat multidrug-resistant tuberculosis. Science 295, 2042–2046 (2002).
  Article CAS Google Scholar
• Cohen, T., Sommers, B. & Murray, M. The effect of drug resistance on the fitness of Mycobacterium tuberculosis. Lancet Infect. Dis. 3, 13–21 (2003).
  Article Google Scholar
• Martinez, J. L., Baquero, F. & Andersson, D. I. Predicting antibiotic resistance. Nature Rev. Microbiol. 5, 958–965 (2007).
  Article CAS Google Scholar
• Rosas-Magallanes, V. et al. Horizontal transfer of a virulence operon to the ancestor of Mycobacterium tuberculosis. Mol. Biol. Evol. 23, 1129–1135 (2006).
  Article CAS Google Scholar
• Coros, A., DeConno, E. & Derbyshire, K. M. IS_6110_, a Mycobacterium tuberculosis complex-specific insertion sequence, is also present in the genome of Mycobacterium smegmatis, suggestive of lateral gene transfer among mycobacterial species. J. Bacteriol. 190, 3408–3410 (2008).
  Article CAS Google Scholar
• Becq, J. et al. Contribution of horizontally acquired genomic islands to the evolution of the tubercle bacilli. Mol. Biol. Evol. 24, 1861–1871 (2007).
  Article CAS Google Scholar
• Hazbon, M. H. et al. Population genetics study of isoniazid resistance mutations and evolution of multidrug-resistant Mycobacterium tuberculosis. Antimicrob. Agents Chemother. 50, 2640–2649 (2006).
  Article CAS Google Scholar
• Prammananan, T. et al. Distribution of rpoB mutations among multidrug-resistant Mycobacterium tuberculosis (MDRTB) strains from Thailand and development of a rapid method for mutation detection. Clin. Microbiol. Infect. 14, 446–453 (2008).
  Article CAS Google Scholar
• Caws, M. et al. The influence of host and bacterial genotype on the development of disseminated disease with Mycobacterium tuberculosis. PLoS Pathog. 4, e1000034 (2008).
  Article Google Scholar
• Espinal, M. A. et al. Standard short-course chemotherapy for drug-resistant tuberculosis: treatment outcomes in 6 countries. J. Am. Med. Assoc. 283, 2537–2545 (2000).
  Article CAS Google Scholar
• Mak, A. et al. Influence of multidrug resistance on tuberculosis treatment outcomes with standardized regimens. Am. J. Respir. Crit. Care Med. 178, 306–312 (2008).
  Article Google Scholar
• Cox, H. et al. Tuberculosis recurrence and mortality after successful treatment: impact of drug resistance. PLoS Med. 3, e384 (2006).
  Article Google Scholar
• Cox, H. S. et al. Risk of acquired drug resistance during short-course directly observed treatment of tuberculosis in an area with high levels of drug resistance. Clin. Infect. Dis. 44, 1421–1427 (2007).
  Article CAS Google Scholar
• Nathanson, E. et al. Multidrug-resistant tuberculosis management in resource-limited settings. Emerg. Infect. Dis. 12, 1389–1397 (2006).
  Article Google Scholar
• Leimane, V. et al. Clinical outcome of individualized treatment of multidrug-resistant tuberculosis in Latvia: a retrospective cohort study. Lancet 365, 318–326 (2005).
  Article Google Scholar
• Furin, J. The clinical management of drug-resistant tuberculosis. Curr. Opin. Pulm. Med. 13, 212–217 (2007).
  Article CAS Google Scholar
• Shin, S. S. et al. Long-term follow-up for multidrug-resistant tuberculosis. Emerg. Infect. Dis. 12, 687–688 (2006).
  Article Google Scholar
• Keshavjee, S. et al. Treatment of extensively drug-resistant tuberculosis in Tomsk, Russia: a retrospective cohort study. Lancet 372, 1403–1409 (2008).
  Article Google Scholar
• Mitnick, C. S. et al. Comprehensive treatment of extensively drug-resistant tuberculosis. N. Engl. J. Med. 359, 563–574 (2008).
  Article CAS Google Scholar
• World Health Organization. Global tuberculosis control 2008: surveillance, planning, financing (WHO, Geneva, 2008).
• World Health Organization. Green Light Committee Initiative. Annual report (WHO, Geneva, 2007).
• Kwon, Y. S. et al. Treatment outcomes for HIV-uninfected patients with multidrug-resistant and extensively drug-resistant tuberculosis. Clin. Infect. Dis. 47, 496–502 (2008).
  Article Google Scholar
• Bonilla, C. A. et al. Management of extensively drug-resistant tuberculosis in Peru: cure is possible. PLoS One 3, e2957 (2008).
  PubMed PubMed Central Google Scholar
• Cox, H. S., Morrow, M. & Deutschmann, P. W. Long term efficacy of DOTS regimens for tuberculosis: systematic review. Br. Med. J. 336, 484–487 (2008).
  Article Google Scholar
• Chan, E. D., Strand, M. J. & Iseman, M. D. Treatment outcomes in extensively resistant tuberculosis. N. Engl. J. Med. 359, 657–659 (2008).
  Article CAS Google Scholar
• Mariam, D. H., Mengistu, Y., Hoffner, S. E. & Andersson, D. I. Effect of rpoB mutations conferring rifampin resistance on fitness of Mycobacterium tuberculosis. Antimicrob. Agents Chemother. 48, 1289–1294 (2004).
  Article CAS Google Scholar
• Gagneux, S. et al. The competitive cost of antibiotic resistance in Mycobacterium tuberculosis. Science 312, 1944–1946 (2006).
  Article CAS Google Scholar
• Strauss, O. J. et al. Spread of a low-fitness drug-resistant Mycobacterium tuberculosis strain in a setting of high human immunodeficiency virus prevalence. J. Clin. Microbiol. 46, 1514–1516 (2008).
  Article CAS Google Scholar
• European Concerted Action on New Generation Genetic Markers and Techniques for the Epidemiology and Control of Tuberculosis. Beijing/W genotype Mycobacterium tuberculosis and drug resistance. Emerg. Infect. Dis. 12, 736–743 (2006).
• Sun, Y. J. et al. Genotype and phenotype relationships and transmission analysis of drug-resistant tuberculosis in Singapore. Intern. J. Tuberc. Lung Dis. 11, 436–442 (2007).
  Google Scholar
• Cox, H. S. et al. The Beijing genotype and drug resistant tuberculosis in the Aral Sea region of Central Asia. Respir. Res. 6, 134 (2005).
  Article Google Scholar
• Marais, B. J. et al. Beijing and Haarlem genotypes are overrepresented among children with drug-resistant tuberculosis in the Western Cape Province of South Africa. J. Clin. Microbiol. 44, 3539–3543 (2006).
  Article CAS Google Scholar
• Lopez, B. et al. A marked difference in pathogenesis and immune response induced by different Mycobacterium tuberculosis genotypes. Clin. Exper. Immunol. 133, 30–37 (2003).
  Article CAS Google Scholar
• Toungoussova, O. S., Caugant, D. A., Sandven, P., Mariandyshev, A. O. & Bjune, G. Impact of drug resistance on fitness of Mycobacterium tuberculosis strains of the W-Beijing genotype. FEMS Immunol. Med. Microbiol. 42, 281–290 (2004).
  Article CAS Google Scholar
• Blower, S. & Supervie, V. Predicting the future of XDR tuberculosis. Lancet Infect. Dis. 7, 443 (2007).
  Article Google Scholar
• Cohen, T. & Murray, M. Modeling epidemics of multidrug-resistant M. tuberculosis of heterogeneous fitness. Nature Med. 10, 1117–1121 (2004).
  Article CAS Google Scholar
• Blower, S. M. & Chou, T. Modeling the emergence of the 'hot zones': tuberculosis and the amplification dynamics of drug resistance. Nature Med. 10, 1111–1116 (2004).
  Article CAS Google Scholar
• DeRiemer, K. et al. Does DOTS work in populations with drug-resistant tuberculosis? Lancet 365, 1239–1245 (2005).
  Article Google Scholar
• Espinal, M. A. & Dye, C. Can DOTS control multidrug-resistant tuberculosis? Lancet 365, 1206–1209 (2005).
  Article Google Scholar
• Wu, P. et al. Age-period-cohort analysis of tuberculosis notifications in Hong Kong from 1961 to 2005. Thorax 63, 312–316 (2008).
  Article CAS Google Scholar
• Dye, C. in Clinical Tuberculosis 4th edn (eds Davies, P. D. O., Barnes, P. F. & Gordon, S. B.) 21–41 (Hodder Arnold, London, 2008).
  Google Scholar
• Dye, C., Garnett, G. P., Sleeman, K. & Williams, B. G. Prospects for worldwide tuberculosis control under the WHO DOTS strategy. Directly observed short-course therapy. Lancet 352, 1886–1891 (1998).
  Article CAS Google Scholar
• Styblo, K. & Bumgarner, J. R. Tuberculosis can be controlled with existing technologies: evidence. Tubercul. Surveill. Res. Unit. Progress Report 2, 60–72 (1991).
  Google Scholar
• Nardell, E. A. Environmental infection control of tuberculosis. Semin. Respir. Infect. 18, 307–319 (2003).
  Article Google Scholar
• Bock, N. N., Jensen, P. A., Miller, B. & Nardell, E. Tuberculosis infection control in resource-limited settings in the era of expanding HIV care and treatment. J. Infect. Dis. 196 (Suppl. 1), 108–113 (2007).
  Article Google Scholar
• World Health Organization. Tuberculosis infection control in the era of expanding care and treatment (WHO, Geneva, 2007).
• World Health Organization. Guidelines for the programmatic management of drug-resistant tuberculosis (WHO, Geneva, 2006).
• Cobelens, F. G. et al. Scaling up programmatic management of drug-resistant tuberculosis: a prioritized research agenda. PLoS Med. 5, e150 (2008).
  Article Google Scholar
• Mitnick, C. D., Appleton, S. C. & Shin, S. S. Epidemiology and treatment of multidrug resistant tuberculosis. Semin. Respir. Crit. Care Med. 29, 499–524 (2008).
  Article Google Scholar
• Nunn, A. J., Phillips, P. P. & Gillespie, S. H. Design issues in pivotal drug trials for drug sensitive tuberculosis (TB). Tuberculosis (Edinb.) 88 (Suppl. 1), 85–92 (2008).
  Article Google Scholar
• Borgdorff, M. W., Floyd, K. & Broekmans, J. F. Interventions to reduce tuberculosis mortality and transmission in low- and middle-income countries. Bull. World Health Organ. 80, 217–227 (2002).
  PubMed PubMed Central Google Scholar
• Styblo, K. Epidemiology of Tuberculosis (KNCV Tuberculosis Foundation, The Hague, 1991).
  Google Scholar
• China Tuberculosis Control Collaboration. The effect of tuberculosis control in China. Lancet 364, 417–422 (2004).
• Dye, C., Ottmani, S., Laasri, L. & Bencheikh, N. The decline of tuberculosis epidemics under chemotherapy: a case study in Morocco. Int. J. Tuberc. Lung Dis. 11, 1225–1231 (2007).
  CAS PubMed Google Scholar
• Suarez, P. G. et al. The dynamics of tuberculosis in response to 10 years of intensive control effort in Peru. J. Infect. Dis. 184, 473–478 (2001).
  Article CAS Google Scholar